Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CLCN2 | P51788 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28146164 | 0.85 | ALDH1A1 (0.42) | NOTUMP2RX7ALDH1A1 | |
| SCHEMBL2579485 | 0.84 | LMNA (0.41) | CASP1NOTUMP2RX7PDK2 | |
| SCHEMBL19813279 | 0.84 | TSHR (0.40) | TSHRCASP1SMN1; SMN2NOTUMALDH1A1 | |
| SCHEMBL21776979 | 0.83 | NOTUM (0.56) | TSHRCASP1SMN1; SMN2NOTUMALDH1A1 | |
| SCHEMBL8786682 | 0.81 | CES2 (0.42) | TSHRCASP1SMN1; SMN2NOTUMALDH1A1 | |
| SCHEMBL109128 | 0.78 | TSHR (0.48) | TSHRCASP1SMN1; SMN2ALDH1A1GRIK1 | |
| SCHEMBL4232615 | 0.78 | RXRB (0.45) | TSHRNOTUMALDH1A1KDM4EHPGD | |
| SCHEMBL5479400 | 0.76 | RXRB (0.41) | NOTUMALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL2579411 | 0.76 | CES2 (0.50) | TSHRCASP1SMN1; SMN2P2RX7ALDH1A1 | |
| SCHEMBL31392754 | 0.76 | CES2 (0.50) | TSHRCASP1SMN1; SMN2P2RX7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338243-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-06-24 | — | — | US | disclosed |
| US-20220235062-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-28 | — | — | US | disclosed |
| EP-3309161-B1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING A P2X7 MODULATOR | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-18 | — | — | EP | disclosed |
| EP-3191488-B1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-14 | — | — | EP | disclosed |
| US-10323032-B2 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| US-10053462-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-21 | — | — | US | disclosed |
| EP-3321266-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-05-16 | — | — | EP | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| EP-3309161-A1 | P2X7 MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-04-18 | — | — | EP | disclosed |
| US-20180072724-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | US | disclosed |
| EP-2049478-B1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| CN-101511787-B | Substituted N-phenylmethyl-5-oxo-proline-2-amides as P2X 7-receptor antagonists and methods of their use | GLAXO GROUP LTD. (GB) | 2011-11-30 | — | — | CN | disclosed |
| US-8048907-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2011-11-01 | — | — | US | disclosed |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7718693-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| CN-101511787-A | Substituted N-phenylmethyl-5-oxo-proline-2-amides as P2X 7-receptor antagonists and methods of their use | GLAXO GROUP LTD (GB) | 2009-08-19 | — | — | CN | disclosed |
| WO-2009074518-A1 | COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| EP-2049478-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | Glaxo Group Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008003697-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235062-A1 | P2X7 MODULATORS | P2RX7, P2RX4, P2RX1 | TSHR 2552/4885CASP1 562/4885SMN1; SMN2 4479/4885 |
| US-10323032-B2 | P2X7 Modulators | P2RX7, P2RX1, P2RX3 | TSHR 2329/4885CASP1 402/4885SMN1; SMN2 4397/4885 |
| US-10053462-B2 | P2X7 modulators | P2RX1, P2RX5, P2RX7 | TSHR 1088/4885CASP1 260/4885SMN1; SMN2 4647/4885 |
| US-12338243-B2 | P2X7 modulators | P2RX7, P2RX4, P2RX1 | TSHR 2552/4885CASP1 562/4885SMN1; SMN2 4479/4885 |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | TSHR 1498/4885CASP1 255/4885SMN1; SMN2 2202/4885 |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | TSHR 1498/4885CASP1 255/4885SMN1; SMN2 2202/4885 |
| US-20180118749-A1 | P2X7 MODULATORS | P2RX7, P2RX3, P2RX1 | TSHR 1554/4885CASP1 106/4885SMN1; SMN2 2720/4885 |
| US-20180072724-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | TSHR 2329/4885CASP1 402/4885SMN1; SMN2 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.